Achalasia Treatment

Achalasia treatment cannot usually correct the underlying nerve dysfunction, so its central therapeutic target is resistance at the lower esophageal sphincter. Pneumatic dilation, laparoscopic Heller myotomy, and peroral endoscopic myotomy reduce that resistance, allowing food to pass more easily. Symptom improvement can therefore occur even when normal esophageal peristalsis does not return.

Botulinum toxin injection and medicines may help selected patients by providing temporary symptom relief, but they do not restore the abnormal nerve function associated with achalasia. Their limited duration distinguishes them from pneumatic dilation and myotomy-based procedures, which are intended to produce a more sustained reduction in lower esophageal sphincter resistance.

Disease subtype is one factor used to select among available treatments. Because achalasia can present with different subtypes, clinicians consider subtype together with the patient’s general health, procedural risk, and need for long-term symptom control. This individualized assessment helps match the intervention with the expected therapeutic goals and clinical circumstances.

A treatment choice must account for more than the presence of swallowing symptoms. Patient health and procedural risk help determine whether a pneumatic, laparoscopic, endoscopic, medication-based, or injection approach is appropriate. These considerations are weighed alongside disease subtype and the clinician’s goal of achieving durable symptom control.

Improvement is reflected by reduced dysphagia, regurgitation, and chest discomfort. Clinicians can also consider whether treatment improves nutritional status, since easier passage of food may support better intake. These outcomes provide practical evidence that lowering sphincter resistance has improved the patient’s daily symptoms and ability to maintain nutrition.

Treatment aims not only to relieve current symptoms but also to limit further esophageal dilation. Persistent difficulty moving food through the esophagus can remain clinically important even when individual symptoms fluctuate. Therefore, long-term planning considers both symptom control and the broader objective of preventing continued enlargement of the esophagus.